COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD
HC Q study #129
Source   PDF   Share   Tweet
See all 143 studies
9/23
Negative
Late treatment study
Ulrich et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa446 (Peer Reviewed)
Treating Covid-19 With Hydroxych loroquine (TEACH): A Multicenter, Double-Blind, Randomized Controlled Trial in Hospitalized Patients
Small RCT on very late stage use of HC Q, with 48% on oxygen at baseline. 67 HC Q patients, 61 control.
Baseline states were not comparable - 82% more HC Q patients had the highest severity at baseline, there was 32% more male HC Q patients, and 44% more control patients used AZ. The HC Q group also had significantly more patients with cerebrovascular disease, cardiovascular disease (non-hypertension), renal disease (non-dialysis), and a history of organ transplants.
30 day mortality RR 1.06, p = 1.0.
death, ↑6.0%, p=1.00
Source   PDF   Share   Tweet
See all 143 studies
Please send us corrections, updates, or comments.
Submit